ternspharma.com (TERN): Net earnings per share for the last 12 months

TERN (Terns Pharma) - company brandmark

Terns Pharmaceuticals (TERN) TTM net income per share demonstrates the efficiency of its asset-light model utilizing outsourced drug production. The current metric value of -1.03 correlates with plans to monetize fatty liver disease medications through insurance reimbursements. The development of precision oncology programs to diversify the portfolio provides additional stability to the corporate structure.

Terns Corp (TERN) - Earnings per share for the last four quarters from 07/04/2022 to 05/16/2026

Analytical breakdowns for Terns Corp (TERN)

- stock price and consensus target price:
Stock Price Terns Pharma|TERN - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Terns Pharmaceuticals, Inc.|TERN - Aggregate Business Value
- balance sheet net asset value indicators:
Accounting Value per Share Terns Pharmaceuticals|TERN - Total Net Assets|Market Capitalization to Book Value Ratio ternspharma.com|TERN - Company Assets
- business debt structure and liquidity details:
Debt to Equity Terns Pharmaceuticals|TERN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Terns Pharmaceuticals, Inc.|TERN - Company Aggregate Debt|Debt to Book Capitalization Ratio Terns Pharmaceuticals|TERN - Long-Term Debt Volume|Company Current Liabilities Terns Pharmaceuticals|Quick Liquidity ternspharma.com
- earnings and valuation multiples indicators:
TERN - Profit After Tax|Projected Future Earnings Terns Pharmaceuticals|TERN - Company Value to Net Income|Forward P/E Multiple Terns Pharma|TERN - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Terns Corp|TERN - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Terns Pharmaceuticals|TERN - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ternspharma.com|TERN - Earnings growth in current year|Earnings growth forecast for next year Terns Pharmaceuticals
- sales revenue and business income indicators:
TERN - Company Sales|Projected Sales Volume Terns Corp|TERN - Price to Sales|Forward Price-to-Revenue Multiple Terns Pharma
Fundamental valuation:TERN - Terns Pharma
Mass-produced product of Terns Pharmaceuticals Inc

Diversifying biomaterial logistics minimizes operational risks for Terns Pharmaceuticals (TERN), establishing a foundation for stable capitalization growth. The earnings per share over the last four quarters measure net income distributed across the current number of shares, allowing for an assessment of real business efficiency without seasonal fluctuations. Analyzing this vector helps determine the asset's fundamental value and identify overbought conditions in the stock in a timely manner.

Competitors of Terns Pharmaceuticals

Phathom Pharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Ironwood Pharma IRWD|CURX (curanexpharma.com) - Net earnings per share for the last 12 months|IMRN: Earnings per share for the last four quarters|EVOK (Evoke Pharma Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months enterothera.com ENTO|Net earnings per share (EPS TTM) RDHL|Net earnings per share (EPS TTM) palisadebio.com (PALI)|Net earnings per share (EPS TTM) JAGX (Jaguar Health Inc)|Biora Therapeutics, Inc (BIOR) - Net earnings per one share for the last twelve months|MORF - Earnings per share for the last twelve months